Filtered By:
Source: The American Journal of Cardiology
Condition: Atrial Fibrillation
This page shows you your search results in order of relevance. This is page number 14.
Order by Relevance | Date
Total 336 results found since Jan 2013.
OP-045 Sigmoid Septum with Left Ventricular Outflow Tract Obstruction: Is it Just a Heart Aging?
The evaluation of myocardial infarction, stroke and atrial fibrillation incidence among patients with sigmoid septum and left ventricular outflow tract obstruction.
Source: The American Journal of Cardiology - March 12, 2015 Category: Cardiology Authors: Paloma Manea, Gabriela Cascaval Tags: Oral Abstract Source Type: research
Relation between Dabigatran Concentration, as Assessed Using the Direct Thrombin Inhibitor Assay, and Activated Clotting Time/Activated Partial Thromboplastin Time in Patients with Atrial Fibrillation
In this study, we aimed to assess the associations between the dabigatran concentration (calculated via plasma-diluted thrombin time, as assessed using the Hemoclot® assay) and the activated partial thromboplastin time (aPTT) and activated clotting time (ACT). We recruited 137 patients with atrial fibrillation who were receiving a normal dose of dabigatran (300 mg/day) or a reduced dose of dabigatran (220 mg/day, usually administered to patients who were elderly, had moderate renal dysfunction, or who were also receiving verapamil).
Source: The American Journal of Cardiology - March 25, 2015 Category: Cardiology Authors: Kenji Okubo, Taishi Kuwahara, Katsumasa Takagi, Masateru Takigawa, Jun Nakajima, Yuji Watari, Emiko Nakashima, Kazuya Yamao, Tadashi Fujino, Hiroyuki Tsutsui, Atsushi Takahashi Source Type: research
Balancing the Risk of Bleeding and Stroke in Patients with Atrial Fibrillation after Percutaneous Coronary Intervention (from the AVIATOR-registry)
We describe patterns and determinants of antithrombotic prescriptions in this population. The AVIATOR (Antithrombotic strategy Variability In ATrial fibrillation and Obstructive coronary disease Revascularized with PCI) Registry was an international observational study of 859 consecutive patients with AF undergoing PCI between 2009 and 2011.
Source: The American Journal of Cardiology - April 7, 2015 Category: Cardiology Authors: Marco G. Mennuni, Jonathan L. Halperin, Sameer Bansilal, Mikkel M. Schoos, Kleanthis N. Theodoropoulos, Omar A. Meelu, Samantha Sartori, Daniele Giacoppo, Chiara Bernelli, Pedro R. Moreno, Prakash Krishnan, Usman Baber, Carla Lucarelli, George D. Dangas, Source Type: research
Reply
We appreciate the interest in our article, “Overview of the Food and Drug Administration Circulatory System Devices Panel Meetings on WATCHMAN Left Atrial Appendage Closure Therapy,” and that it stimulated provocative discussion in a letter to the editor. First, the WATCHMAN device was approved with the indication to reduce the risk of thromboembolism from the left atrial appendage (LAA) in patients with non-valvular atrial fibrillation, who are at an increased risk for stroke and systemic embolism based on CHADS2 or CHA2DS2-VASc scores; are deemed by their physicians to be suitable for warfarin; and have an appropriat...
Source: The American Journal of Cardiology - April 23, 2015 Category: Cardiology Authors: Ron Waksman Source Type: research
Balancing the Risk of Bleeding and Stroke in Patients With Atrial Fibrillation After Percutaneous Coronary Intervention (from the AVIATOR Registry)
We describe patterns and determinants of antithrombotic prescriptions in this population. The Antithrombotic Strategy Variability in Atrial Fibrillation and Obstructive Coronary Disease Revascularized with PCI Registry was an international observational study of 859 consecutive patients with AF who underwent PCI from 2009 to 2011.
Source: The American Journal of Cardiology - April 7, 2015 Category: Cardiology Authors: Marco G. Mennuni, Jonathan L. Halperin, Sameer Bansilal, Mikkel M. Schoos, Kleanthis N. Theodoropoulos, Omar A. Meelu, Samantha Sartori, Daniele Giacoppo, Chiara Bernelli, Pedro R. Moreno, Prakash Krishnan, Usman Baber, Carla Lucarelli, George D. Dangas, Tags: Coronary Artery Disease Source Type: research
Meta-analysis of CHADS Score in Predicting Atrial Fibrillation
The CHADS2 score is a validated clinical tool used for the risk stratification of stroke in the presence of atrial fibrillation (AF). Recently, some studies have shown that CHADS2 score may predict the risk of AF, which yielded conflicting results. The purpose of this study is to perform a meta-analysis of observational studies to examine the association between the CHADS2 score and risk of AF. Using PubMed and EMBASE database, we searched published articles to November 2014 to identify studies which evaluated the association between CHADS2 score and the risk of AF.
Source: The American Journal of Cardiology - May 20, 2015 Category: Cardiology Authors: Yajuan Yang, Zhiwei Zhang, Chee Yuan Ng, Guangping Li, Tong Liu Source Type: research
Prevalence and Clinical Determinants of Left Atrial Appendage Thrombus in Patients with Atrial Fibrillation Prior to Pulmonary Vein Isolation
The CHADS2 score is considered a reliable predictor of stroke/thromboembolism risk in patients with atrial fibrillation (AF). However, thromboembolism can occasionally occur even in AF patients with low CHADS2 score (CHADS2 score = 0 or 1). To investigate the incidence and predictors of left atrial appendage (LAA) thrombus (LAAT) formation in patients with AF, we studied consecutive 543 Japanese AF patients who underwent transesophageal echocardiography before pulmonary vein isolation from 2008 to 2012.
Source: The American Journal of Cardiology - August 13, 2015 Category: Cardiology Authors: Makiko Nishikii-Tachibana, Nobuyuki Murakoshi, Yoshihiro Seo, DongZhu Xu, Masayoshi Yamamoto, Tomoko Ishizu, Akiko Atsumi, Tomoko Machino-Ohtsuka, Kenji Kuroki, Hiro Yamasaki, Miyako Igarashi, Yukio Sekiguchi, Kazutaka Aonuma Source Type: research
Cardiac Complications after Community-acquired Pneumonia
We read with interest the article by Cangemi et al “Relation of cardiac complications in the early phase of community –acquired pneumonia to long-term mortality and cardiovascular events”1 published in the August 5th issue of The American Journal of Cardiology. The authors show that 18% of patients with community-acquired pneumonia (CAP) study develop intra-hospital cardiac complications, defined as myocardial infarction (MI) and atrial fibrillation. Furthermore, the authors prospectively show that these cardiac complications in the early phase of CAP are associated with adverse long-term cardiovascular prognosis (wi...
Source: The American Journal of Cardiology - October 15, 2015 Category: Cardiology Authors: Carlos G. Santos-Gallego, Juan Badimon Source Type: research
Cost-Effectiveness of Dabigatran (150 mg Twice Daily) and Warfarin in Patients ≥ 65 Years with Non-Valvular Atrial Fibrillation
Dabigatran has been shown to be superior to warfarin for stroke prevention in non-valvular atrial fibrillation (NVAF) but with higher out-of-pocket costs for patients. Although dabigatran has been shown to be cost-effective from a societal perspective, cost implications for individual patients and insurers are not well-described. We aimed to assess cost perspectives of each payer (Medicare and patient) in relation to administration, monitoring and adverse outcomes for dabigatran and warfarin in patients with and without prescription drug coverage.
Source: The American Journal of Cardiology - October 16, 2015 Category: Cardiology Authors: Brian M. Salata, David W. Hutton, Deborah A. Levine, James B. Froehlich, Geoffrey D. Barnes Source Type: research
Meta-Analysis of Renal Function on the Safety and Efficacy of Novel Oral Anticoagulants for Atrial Fibrillation
Novel oral anticoagulants (NOACs) are safe and effective for the prevention of stroke or systemic embolism (S/SE) in atrial fibrillation (AF). The efficacy and safety of NOACs compared to warfarin has not been systematically assessed in subjects with mild or moderate renal dysfunction. We performed a meta-analysis of the randomized clinical trials that compared efficacy and safety (major bleeding) outcomes of NOACs compared to warfarin for the treatment of nonvalvular AF and had available data on renal function.
Source: The American Journal of Cardiology - October 16, 2015 Category: Cardiology Authors: Freddy Del-Carpio Munoz, S. Michael Gharacholou, Thomas M. Munger, Paul A. Friedman, Samuel J. Asirvatham, Douglas L. Packer, Peter A. Noseworthy Source Type: research
A Simple and Portable Algorithm for Identifying Atrial Fibrillation in the Electronic Medical Record
Atrial fibrillation (AF) is common and increases stroke risk and mortality. Many knowledge gaps remain with respect to practice patterns and outcomes. Electronic medical records (EMR) may serve as powerful research tools if AF status can be properly ascertained. We sought to develop an algorithm for identifying individuals with and without AF in the EMR and compare it to previous methods. Using a hospital network EMR (n=5,737,846), we randomly selected 8,200 individuals seen at a large academic medical center in January 2014 to derive and validate seven AF classification schemas (4 case and 3 control) in order to construct...
Source: The American Journal of Cardiology - November 5, 2015 Category: Cardiology Authors: Shaan Khurshid, John Keaney, Patrick T. Ellinor, Steven A. Lubitz Source Type: research
Cost-Effectiveness of Dabigatran (150 mg Twice Daily) and Warfarin in Patients ≥65 Years With Nonvalvular Atrial Fibrillation
Dabigatran has been shown to be superior to warfarin for stroke prevention in nonvalvular atrial fibrillation (NVAF) but with higher out-of-pocket costs for patients. Although dabigatran has been shown to be cost effective from a societal perspective, cost implications for individual patients and insurers are not well described. We aimed to assess cost perspectives of each payer (Medicare and patient) in relation to administration, monitoring, and adverse outcomes for dabigatran and warfarin in patients with and without prescription drug coverage.
Source: The American Journal of Cardiology - October 16, 2015 Category: Cardiology Authors: Brian M. Salata, David W. Hutton, Deborah A. Levine, James B. Froehlich, Geoffrey D. Barnes Tags: Arrhythmias and Conduction Disturbances Source Type: research
Usefulness of Holter Monitoring for Detecting Atrial Fibrillation after Stoke or Transient Ischemic Attack
The sensitivity of a diagnostic test is ideally calculated by comparing the test’s assessments to a truth determined by another (perfect) test considered to be the gold standard. However, in many cases, there is no perfect gold standard.1 When it exists, assessment by the gold standard can be inaccessible, costly, or highly invasive. Using the best available but imperfect diagnostic test as gold standard can lead to substantial error in the estimation of its diagnostic accuracy.1 The detection of atrial fibrillation (AF) after ischemic stroke is not an exception to this phenomenon.
Source: The American Journal of Cardiology - November 11, 2015 Category: Cardiology Authors: Lauren E. Cipriano, Luciano A. Sposato Source Type: research
Effects of Oral Anticoagulant Therapy in Medical In-patients ≥65 Years of Age with Atrial Fibrillation
In this retrospective cohort observational study we investigated mortality, ischemic and hemorrhagic events, in patients ≥65 years of age with atrial fibrillation (AF) consecutively discharged from an Acute Geriatric Ward in the period 2010-2013. Stroke and bleeding risk were evaluated using CHA2DS2-VASC and HAS-BLED scores. Comorbidity, cognitive status and functional autonomy were evaluated using standardized scales. Independent associations between clinical variables, including use of Vitamin K Antagonists (VKAs)-based oral anticoagulant therapy (OAT), and all-cause mortality, fatal and non-fatal ischemic and hemorrha...
Source: The American Journal of Cardiology - December 1, 2015 Category: Cardiology Authors: Mario Bo, Irene Sciarrillo, Federica Li Puma, Marco Badinella Martini, Yolanda Falcone, Marina Iacovino, Enrica Grisoglio, Elena Menditto, Gianfranco Fonte, Enrico Brunetti, Guido Maggiani, Giovanni Carlo Isaia, Fiorenzo Gaita Source Type: research
Anticoagulation, CHADSVASc Score and Thromboembolic Risk of Cardioversion of Acute Atrial Fibrillation (from the FinCV Study)
The efficacy of the anticoagulation in prevention thromboembolic complications (TEC) and the usefulness of the CHA2DS2VASc score for assessing stroke risk during cardioversion of acute atrial fibrillation (AF) are unclear. Thus, our objectives were to assess the ability of the CHA2DS2VASc score to predict TEC and to evaluate the efficacy of anticoagulation in the prevention of TEC in Finnish CardioVersion (FinCV) study. The FinCV is a retrospective, multicenter study of 3143 patients, who underwent 7660 cardioversions for acute AF.
Source: The American Journal of Cardiology - January 28, 2016 Category: Cardiology Authors: Toni Grönberg, Juha E.K. Hartikainen, Ilpo Nuotio, Fausto Biancari, Antti Ylitalo, K. E. Juhani Airaksinen Source Type: research
